In the context of several pharmaceutical companies that reported sales declines in the second quarter due to COVID-19, AstraZeneca represents a rare exception, thanks to the strong performance of its cancer drugs. In the second quarter, AZ’s oncology portfolio generated $ 2.61 billion, a 24% year-over-year increase with constant exchange …
Read More »Tagrisso and Other Cancer Drugs Give AstraZeneca One of Pharmaceutical Industry’s Rare Pandemic Sales Profits
